S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy for stage III non-small cell lung cancer: a pilot randomized controlled trial

Radiation Oncology

Dawei Sun¹  Junfeng Wang¹  Chaoyang Yang¹  Jianyu Xu¹  Shidong Xu¹  Lei Yao¹ 

[1] Department of Chest Surgery, Third Affiliated Hospital of Harbin Medical University, Haping Road No.150, Nangang District, Harbin 150081, Heilongjiang Province, China

关键词: Non-small-cell lung cancer;    Radiotherapy;    Cisplatin;    S-1;   

Others  :  1150150
DOI  :  10.1186/s13014-014-0306-3

 received in 2014-10-14, accepted in 2014-12-15,  发布年份 2015

【 摘 要 】

Background

We investigated the efficacy and safety of S-1 and cisplatin with concurrent thoracic radiation (SCCR) over cisplatin alone plus concurrent thoracic radiation (CCR) for unresectable stage III non-small-cell lung cancer (NSCLC).

Methods

Between January 2009 and November 2011, 40 eligible patients with NSCLC were included and divided randomly into two groups. Twenty patients received SCCR with S-1 (orally at 40 mg/m² per dose, b.i.d.) on days 1 through 14, cisplatin (60 mg/m² on day 1) every 4 weeks for two cycles, and radiotherapy (60 Gy/30 fractions over 6 weeks) beginning on day 1. Twenty subjects received CCR (cisplatin and radiotherapy, the same as for SCCR).

Results

The 3-year overall response rate was 59.3% and 52.4% for the SCCR and CCR groups, respectively, and the difference was statistically significant, while the median overall survival was 33 months (range, 4–41 months) and 24 months (range, 2–37 months), respectively (P = 0.048). The median progression-free survival was 31 months for SCCR (range, 5–39 months), whereas it was 20 months (range, 2–37 months) for CCR (P = 0.037). The toxicity profile was similar in both groups.

Conclusion

In summary, we demonstrated that S-1 and cisplatin with concurrent thoracic radiation was more effective than cisplatin plus radiotherapy in NSCLC patients with acceptable toxicity.

Trial registration

Chinese Clinical Trials Register: ChiCTR-TRC-13003997 webcite.

【 授权许可】

   
2015 Yao et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Fig. 5.

【 参考文献 】

• [1]van Meerbeeck JP. Staging of non-small cell lung cancer: consensus, controversies and challenges. Lung Cancer. 2001; 34 Suppl 2:S95-107.
• [2]Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S et al.. American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004; 22:330-53.
• [3]Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S et al.. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol. 1999; 17:2692-9.
• [4]Curran W, Scott C, Langer C. Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer: report of Radiation Therapy Oncology Group (RTOG) 9410. Lung Cancer. 2000; 29 Suppl 1:93.
• [5]Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P et al.. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced nonsmall-cell lung cancer. J Clin Oncol. 2010; 28:2181-90.
• [6]Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S et al.. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer. 2001; 85:939-43.
• [7]Ichinose Y, Yoshimori K, Sakai H, Nakai Y, Sugiura T, Kawahara M et al.. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res. 2004; 10:7860-4.
• [8]Kubota K, Sakai H, Yamamoto N, Kunitoh H, Nakagawa K, Takeda K et al.. A multi-institution phase I/II trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2010; 5:702-6.
• [9]TNM Classification of Malignant Tumours. Wiley-Liss, New York; 2002.
• [10]Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al.. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92:205-16.
• [11]Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events v3.0. 2006, Aug 9 (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf)
• [12]Sekine I, Noda K, Oshita F, Yamada K, Tanaka M, Yamashita K et al.. Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Cancer Sci. 2004; 95(8):691-5.
• [13]Naito Y, Kubota K, Nihei K, Fujii T, Yoh K, Niho S et al.. Concurrent chemoradiotherapy with cisplatin and vinorelbine for stage III non-small cell lung cancer. J Thorac Oncol. 2008; 3(6):617-22.
• [14]Kawaguchi T, Takada M, Ando M, Okishio K, Atagi S, Fujita Y et al.. A multi-institutional phase II trial of consolidation S-1 after concurrent chemoradiotherapy with cisplatin andvinorelbine for locally advanced non-small cell lung cancer. Eur J Cancer. 2012; 48(5):672-7.